Navigation Links
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
Date:3/30/2011

in and chronic pain conditions."

About CR845

CR845 is a highly selective, peripherally restricted kappa opioid receptor agonist currently in Phase 2 clinical development for the treatment of post-operative pain.  A randomized, placebo-controlled Phase 2 study has provided evidence of analgesic efficacy of CR845 administered as a single intravenous dose to women following laparoscopic hysterectomy.  In this study, in addition to decreases in reported pain levels, patients receiving CR845 required substantially lower amounts of post-operative opioids and showed a significant reduction in the incidence of post-operative nausea. Cara recently completed a Phase 1b repeat dose safety study of intravenous CR845 and plans to initiate additional Phase 2 efficacy studies of the drug in 2011. In addition, the Company plans to initiate a phase 1 safety and pharmacokinetic study of an oral capsule formulation of CR845 shortly. More than 140 human subjects have been exposed to CR845 to date.  The safety profile of the drug has been excellent with no cases of dysphoric reactions or hallucinations as seen previously with centrally-acting kappa opioids.  

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. In addition to CR845, Cara's current pipeline includes near-term clinical development candidates within multiple proprietary classes of peripherally restricted cannabinoids with preclinical analgesic and anti-inflammatory activity. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen™ technology.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
2. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
3. Osseon™ Therapeutics Introduces Osseoflex® BT Steerable Bone Tamp
4. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
5. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
6. Reportlinker Adds Therapeutics for Immune System Disorders
7. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
8. Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
9. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
10. Echo Therapeutics Announces 2010 Financial Results
11. Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... PRINCETON, N.J. , June 14 Covance Inc. (NYSE: ... Company,s 30th Annual Growth Stock Conference on Wednesday, June 16, 2010 ... the presentation at www.covance.com .  In order to register and download any ... , , ...
... June 14 MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ... Cheshire, England to manage its planned Phase IIb clinical trial ... candidate for treatment of primary multiple sclerosis-related fatigue (PMSF). , ... In an earlier Phase IIa study, MCT-125 ...
Cached Medicine Technology:MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 2MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 3MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 4
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
(Date:4/17/2014)... of chronic inflammation in benign prostate tissue was ... this association was found even in those with ... study published in Cancer Epidemiology, Biomarkers & ... for Cancer Research. , An analysis of prostate ... placebo arm of the Prostate Cancer Prevention Trial ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... determining factor, study finds , , TUESDAY, Jan. 22 (HealthDay ... for fast-moving prostate cancer can save lives, but the ... serious medical problems, a new study shows. , "The ... is a difference in outcome, depending on the gentleman,s ...
... pounds than dieting and exercise do, study shows , , ... gastric lap-band surgery isn,t only for the most obese; it ... , Still, the surgery is extremely expensive and carries risks. ... need alternative ways to shed pounds, said study author John ...
... MENTOR, Ohio, Jan. 22 STERIS Corporation,(NYSE: STE ... authorized a,regular quarterly dividend in the amount of $0.06 ... to shareholders of record at the close,of business on ... of STERIS Corporation is to provide a healthier today ...
... of Navarra PhD in chemistry researcher, Esther Vicente, has ... Her thesis, defended at the Faculty of Sciences in ... describes the synthesis and characterisation of 65 derivatives of ... number of antimalalarial and antituberculosis pharmaceutical drugs currently on ...
... January 22, 2007, Weinheim, DE: Wiley-Blackwell, the scientific, ... Wiley & Sons, Inc., published a comprehensive resource ... function. , Proteins are essential components of all ... and function of each cell and, ultimately, the ...
... how to manipulate the immune system to increase its ... , Published in the current edition of Viral ... new and more effective vaccines against diseases like influenza ... , The study suggests that scientists can boost the ...
Cached Medicine News:Health News:Hormone Therapy Only Helps Some Older Men With Prostate Cancer 2Health News:Gastric Lap-Band Surgery Can Send Diabetes Into Remission 2Health News:Gastric Lap-Band Surgery Can Send Diabetes Into Remission 3Health News:STERIS Corporation Declares Regular Quarterly Dividend 2Health News:STERIS Corporation Declares Regular Quarterly Dividend 3Health News:Research discovers new compounds active against tuberculosis and malaria 2Health News:'The Handbook of Proteins' 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: